Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/21/2025 | Outperform | William Blair | |
| 1/8/2025 | $4.00 | Mkt Outperform | JMP Securities |
| 11/25/2024 | $9.00 | Buy | D. Boral Capital |
| 5/16/2024 | $4.50 | Overweight | Piper Sandler |
| 2/2/2022 | $6.00 | Buy | HC Wainwright & Co. |
| 1/24/2022 | $10.00 | Buy | ThinkEquity |
4 - Context Therapeutics Inc. (0001842952) (Issuer)
4 - Context Therapeutics Inc. (0001842952) (Issuer)
4 - Context Therapeutics Inc. (0001842952) (Issuer)
PHILADELPHIA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that the Company will participate in the following investor conferences: Cantor Global Healthcare Conference 2025Fireside chat: Wednesday, September 3 at 10:55 AM ET in New York, NY1x1 Meetings on September 3 H.C. Wainwright 27th Annual Global Investment ConferenceFireside chat: Monday, September 8 at 3:30 PM ET in New York, NY1x1 Meetings on September 8 For additional information or to request a meeting with Context's management team during
CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 30, 2025, and reported on recent and upcoming business highlights. "We remain focused on progressing our clinical pipeline — CTIM-76, a selective Claudin 6 ("CLDN6") x CD3 bispecific an
Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, announced today that it is presenting a Trial in Progress poster for the Phase 1 clinical trial evaluating CTIM-76 in ovarian, endometrial, and testicular cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30 – June 3, 2025 in Chicago, IL. The Phase 1 clinical trial is an open-label, d
8-K - Context Therapeutics Inc. (0001842952) (Filer)
SCHEDULE 13G/A - Context Therapeutics Inc. (0001842952) (Subject)
SCHEDULE 13G/A - Context Therapeutics Inc. (0001842952) (Subject)
4 - Context Therapeutics Inc. (0001842952) (Issuer)
4 - Context Therapeutics Inc. (0001842952) (Issuer)
4 - Context Therapeutics Inc. (0001842952) (Issuer)
William Blair initiated coverage of Context Therapeutics with a rating of Outperform
JMP Securities initiated coverage of Context Therapeutics with a rating of Mkt Outperform and set a new price target of $4.00
D. Boral Capital initiated coverage of Context Therapeutics with a rating of Buy and set a new price target of $9.00
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced the appointment of Dr. Karen Chagin, M.D. as Chief Medical Officer ("CMO"), effective June 9, 2025. Dr. Chagin succeeds Dr. Karen Smith, M.D., Ph.D., MBA, LLM, who has been serving as interim CMO and will remain a member of the Company's Board of Directors ("Board"). Dr. Chagin brings over a decade of leadership in clinical development and regulatory strategy for T cell therapies in solid tumors at Adaptimmune Therapeutics plc ("Adaptimmune") and Tmunity
Mr. Pasternak brings decades of global pharmaceutical leadership experience Transition further highlights transformation of the Board to lead Context into next phase of growth PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced the appointment of Andy Pasternak as Chairman of its Board of Directors, succeeding Richard Berman, who stepped down from the Board effective January 12, 2025. "I am honored to become the next Chairman of the Board of Directors of Context, where I expect to leverage my experience advising and building fully int
PHILADELPHIA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced the appointments of Karen Smith, MD, PhD, MBA, LLM and Luke Walker, MD, to its Board of Directors. "Karen and Luke's vast experience and proven leadership in the biopharmaceutical industry are tremendous assets for Context at this pivotal stage of our growth," said Martin Lehr, CEO of Context Therapeutics. "Karen's extensive oncology drug development, regulatory, and strategy experience will be invaluable as Context continues to advance its pipeline. Luke brings an extensive track record in
CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 30, 2025, and reported on recent and upcoming business highlights. "We remain focused on progressing our clinical pipeline — CTIM-76, a selective Claudin 6 ("CLDN6") x CD3 bispecific an
CTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, May 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the first quarter ended March 31, 2025, and reported on recent and upcoming business highlights. Martin Lehr, CEO of Context, commented, "We continue to advance our clinical pipeline and are pleased to have two product c
CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, March 20, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2024, and reported on recent and upcoming business highlights. Martin Lehr, CEO of Context, commented, "We believe 2024 was a transformative year for Context, marked by strategic acquisitions, a s
SC 13G/A - Context Therapeutics Inc. (0001842952) (Subject)
SC 13G - Context Therapeutics Inc. (0001842952) (Subject)
SC 13G/A - Context Therapeutics Inc. (0001842952) (Subject)